コンパニオン診断（CDx）開発市場、規模、シェア、動向、産業分析レポート：サービスタイプ別、分析手法別、ターゲット治療領域別、エンドユーザー別、地域別、2025年～2034年の市場予測

Polaris Market Research社の最新調査によると、コンパニオン診断（CDx）開発の世界市場規模は2034年までに17億5,579万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

コンパニオン診断（CDx）開発市場は、特定の治療薬と複雑に関連した特殊な診断テストの作成と生産を中心に展開されています。これらの検査は、どの患者が特定の治療から最も恩恵を受ける可能性が高いかを決定する際に、ヘルスケア専門家を導く重要な情報を提供するために不可欠です。特定のバイオマーカーや遺伝的特徴を特定することで、CDxは個々の患者に合わせた治療を保証し、それによって副作用のリスクを最小限に抑えながら、薬剤の安全性と有効性を高めることができます。このような医薬品と診断薬の共同開発アプローチはプレシジョン・メディシンの基礎であり、ヘルスケアをより個別化された標的治療へと向かわせます。

コンパニオン診断（CDx）開発市場は、個別化医療に向けた世界の推進力と、特にがんをはじめとする疾病の複雑化により、力強い成長を遂げています。より多くの標的治療が開発されるにつれて、適格な患者集団を同定するためのCDxの需要は増加の一途をたどっています。分子生物学、ゲノミクス、次世代シーケンシング（NGS）などの分析技術の開発もこの分野の技術革新に拍車をかけており、新たなバイオマーカーの発見やより洗練された診断ツールの開発を可能にしています。規制機関は、CDxの共同開発および承認に関するガイドラインを提供することで、この市場を形成する上で重要な役割を果たしており、これらの診断法が主流の医療行為にさらに組み込まれています。

コンパニオン診断（CDx）開発市場レポートハイライト：

サービスタイプ別では、臨床バリデーション分野が2024年に最大のシェアを占めました。これは、実際の患者環境において診断薬の有効性を実証する上で不可欠な役割を果たすためです。強固な臨床バリデーションは規制当局の承認に不可欠であり、検査が特定の薬剤に対する患者の反応を正確に予測することを保証します。

分析手法別では、ポリメラーゼ連鎖反応（PCR）分野が2024年に最大のシェアを占めました。これは、その信頼性の高さ、費用対効果の高さ、臨床検査室での利用の広さが証明されているためです。遺伝子標的の検出における高い感度と特異性により、標的治療の指針となるバイオマーカーを同定するための基本技術となっています。

標的治療領域別では、2024年に腫瘍疾患が最大のシェアを占めました。これは主に、様々ながんの世界の有病率の高さと、がん治療における個別化医療の採用増加によるものです。コンパニオン診断は、特定のがん治療に最もよく反応する患者を選択するために不可欠です。

エンドユーザー別では、創薬への多大な投資と新規治療薬とCDxを共同開発する固有の必要性から、2024年には業界プレイヤーのセグメントが大きなシェアを占めています。業界各社の広範なリソースと世界な商業ネットワークにより、複雑な規制要件への対応が可能となり、CDxの採用が促進されます。

地域別では、北米が2024年のコンパニオン診断市場において最大のシェアを占めており、その理由として、先進的なヘルスケアインフラ、高い医療費、新しい診断技術の迅速な導入を促す支援的な規制環境が挙げられます。

コンパニオン診断（CDx）開発市場には、F. Hoffmann-La Roche Ltd.、QIAGEN N.V.、Agilent Technologies, Inc.、Abbott Laboratories、Illumina, Inc.、Myriad Genetics, Inc.、Sysmex Corporation、BioMerieux SA、Thermo Fisher Scientific Inc.、Labcorp、Quest Diagnostics、Guardant Health, Inc.

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のコンパニオン診断（CDx）開発市場の洞察

• 市場スナップショット
• コンパニオン診断（CDx）開発市場力学
  • 促進要因と機会
    • パーソナライズ医療の導入拡大
    • がんの発生率の上昇
  • 抑制要因と課題
    • 複雑で長期にわたる共同開発と承認のプロセス
• PESTEL分析
• コンパニオン診断（CDx）開発市場動向
• バリューチェーン分析
• COVID-19の影響分析

第5章 世界のコンパニオン診断（CDx）開発市場：サービスタイプ別

• 主な調査結果
• イントロダクション
• 実現可能性調査
• アッセイ開発
• 分析検証
• 臨床検証
• 製造業

第6章 世界のコンパニオン診断（CDx）開発市場：分析技術別

• 主な調査結果
• イントロダクション
• NGS
• PCR
• IHC
• フローサイトメトリー
• その他

第7章 世界のコンパニオン診断（CDx）開発市場：ターゲット治療領域別

• 主な調査結果
• イントロダクション
• 腫瘍性疾患
• 非腫瘍性疾患

第8章 世界のコンパニオン診断（CDx）開発市場：エンドユーザー別

• 主な調査結果
• イントロダクション
• 業界企業
• 業界外企業

第9章 世界のコンパニオン診断（CDx）開発市場：地域別

• 主な調査結果
• イントロダクション
  • コンパニオン診断（CDx）開発市場評価：地域別、2020～2034年
• 北米
  • 北米：サービスタイプ別、2020～2034年
  • 北米：分析技術別、2020～2034年
  • 北米：ターゲット治療領域別、2020年～2034年
  • 北米：エンドユーザー別、2020～2034年
  • 米国
  • カナダ
• 欧州
  • 欧州：サービスタイプ別、2020～2034年
  • 欧州：分析技術別、2020～2034年
  • 欧州：ターゲット治療領域別、2020～2034年
  • 欧州：エンドユーザー別、2020～2034年
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • オランダ
  • ロシア
  • その他欧州
• アジア太平洋
  • アジア太平洋地域：サービスタイプ別、2020～2034年
  • アジア太平洋地域：分析手法別、2020～2034年
  • アジア太平洋地域：ターゲット治療領域別、2020年～2034年
  • アジア太平洋地域：エンドユーザー別、2020～2034年
  • 中国
  • インド
  • マレーシア
  • 日本
  • インドネシア
  • 韓国
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ
  • 中東・アフリカ：サービスタイプ別、2020～2034年
  • 中東・アフリカ：分析手法別、2020～2034年
  • 中東・アフリカ：ターゲット治療領域別、2020年～2034年
  • 中東・アフリカ：エンドユーザー別、2020～2034年
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東とアフリカ
• ラテンアメリカ
  • ラテンアメリカ：サービスタイプ別、2020～2034年
  • ラテンアメリカ：分析手法別、2020～2034年
  • ラテンアメリカ：ターゲット治療領域別、2020年～2034年
  • ラテンアメリカ：エンドユーザー別、2020～2034年
  • メキシコ
  • ブラジル
  • アルゼンチン
  • その他ラテンアメリカ

第10章 競合情勢

• 拡大と買収の分析
  • 拡大
  • 買収
• 提携/協業/合意/公開

第11章 企業プロファイル

• Abbott Laboratories
• Agilent Technologies, Inc.
• BioMerieux SA
• F. Hoffmann-La Roche Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Labcorp
• Myriad Genetics, Inc.
• QIAGEN N.V.
• Quest Diagnostics
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

List of Tables:

• Table 1 Global Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 2 Global Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 3 Global Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 4 Global Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 5 North America: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 6 North America: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 7 North America: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 8 North America: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 9 U.S.: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 10 U.S.: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 11 U.S.: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 12 U.S.: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 13 Canada: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 14 Canada: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 15 Canada: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 16 Canada: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 17 Europe: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 18 Europe: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 19 Europe: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 20 Europe: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 21 UK: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 22 UK: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 23 UK: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 24 UK: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 25 France: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 26 France: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 27 France: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 28 France: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 29 Germany: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 30 Germany: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 31 Germany: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 32 Germany: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 33 Italy: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 34 Italy: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 35 Italy: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 36 Italy: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 37 Spain: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 38 Spain: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 39 Spain: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 40 Spain: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 41 Netherlands: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 42 Netherlands: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 43 Netherlands: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 44 Netherlands: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 45 Russia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 46 Russia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 47 Russia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 48 Russia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 49 Rest of Europe: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 50 Rest of Europe: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 51 Rest of Europe: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 52 Rest of Europe: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 53 Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 54 Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 55 Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 56 Asia Pacific: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 57 China: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 58 China: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 59 China: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 60 China: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 61 India: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 62 India: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 63 India: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 64 India: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 65 Malaysia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 66 Malaysia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 67 Malaysia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 68 Malaysia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 69 Japan: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 70 Japan: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 71 Japan: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 72 Japan: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 73 Indonesia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 74 Indonesia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 75 Indonesia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 76 Indonesia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 77 South Korea: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 78 South Korea: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 79 South Korea: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 80 South Korea: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 81 Australia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 82 Australia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 83 Australia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 84 Australia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 85 Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 86 Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 87 Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 88 Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 89 Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 90 Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 91 Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 92 Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 93 Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 94 Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 95 Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 96 Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 97 UAE: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 98 UAE: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 99 UAE: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 100 UAE: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 101 Israel: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 102 Israel: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 103 Israel: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 104 Israel: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 105 South Africa: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 106 South Africa: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 107 South Africa: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 108 South Africa: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 109 Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 110 Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 111 Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 112 Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 113 Latin America: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 114 Latin America: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 115 Latin America: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 116 Latin America: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 117 Mexico: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 118 Mexico: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 119 Mexico: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 120 Mexico: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 121 Brazil: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 122 Brazil: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 123 Brazil: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 124 Brazil: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 125 Argentina: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 126 Argentina: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 127 Argentina: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 128 Argentina: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• Table 129 Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• Table 130 Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• Table 131 Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• Table 132 Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)

List of Figures:

• Figure 1. Global Companion Diagnostics (Cdx) Development Market, 2020-2034 (USD Million)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Price
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Type of Service
• Figure 7. Global Companion Diagnostics (Cdx) Development Market, by Type of Service, 2024 & 2034 (USD Million)
• Figure 8. Market by Analytical Technique
• Figure 9. Global Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2024 & 2034 (USD Million)
• Figure 10. Market by Target Therapeutic Area
• Figure 11. Global Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2024 & 2034 (USD Million)
• Figure 12. Market by End User
• Figure 13. Global Companion Diagnostics (Cdx) Development Market, by End User, 2024 & 2034 (USD Million)

The global companion diagnostics (CDx) development market size is expected to reach USD 1,755.79 million by 2034, according to a new study by Polaris Market Research. The report "Companion Diagnostics (Cdx) Development Market Size, Share, Trends, Industry Analysis Report By Type of Service (Feasibility Studies, Assay Development), By Analytical Technique, By Target Therapeutic Area, By End User, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The companion diagnostics (CDx) development market revolves around the creation and production of specialized diagnostic tests that are intricately linked with specific therapeutic drugs. These tests are vital for providing crucial information that guides healthcare professionals in determining which patients are most likely to benefit from a particular treatment. By identifying specific biomarkers or genetic characteristics, CDx ensures that treatments are tailored to individual patients, thereby enhancing both the safety and effectiveness of medications while minimizing the risk of adverse reactions. This co-development approach between a drug and its diagnostic is a cornerstone of precision medicine, moving healthcare toward more personalized and targeted interventions.

The companion diagnostics development market is experiencing strong growth, driven by a global push toward personalized medicine and the increasing complexity of diseases, especially cancer. As more targeted therapies are developed, the demand for CDx to identify eligible patient populations continues to rise. Advancements in molecular biology, genomics, and analytical techniques such as next-generation sequencing (NGS) are also fueling innovation in this sector, allowing for the discovery of new biomarkers and the development of more sophisticated diagnostic tools. Regulatory agencies play a key role in shaping this market by providing guidelines for the co-development and approval of CDx, further integrating these diagnostics into mainstream medical practice.

Companion Diagnostics Development Market Report Highlights:

By type of service, the clinical validation segment held the largest share in 2024 due to its essential role in demonstrating a diagnostic's effectiveness in real-world patient settings. Robust clinical validation is critical for regulatory approval, ensuring the test accurately predicts patient response to a specific drug.

By analytical technique, the polymerase chain reaction (PCR) segment held the largest share in 2024 owing to its proven reliability, cost-effectiveness, and widespread use in clinical labs. Its high sensitivity and specificity in detecting genetic targets make it a fundamental technology for identifying biomarkers that guide targeted therapies.

By target therapeutic area, the oncological disorders segment held the largest share in 2024, primarily driven by the high global prevalence of various cancers and the increasing adoption of personalized medicine in cancer treatment. Companion diagnostics are vital for selecting patients who will best respond to specific cancer therapies.

By end user, the industry players segment held a larger share in 2024 due to their significant investments in drug discovery and their inherent need to co-develop CDx alongside new therapeutics. Their extensive resources and global commercial networks enable them to navigate complex regulatory requirements and drive CDx adoption.

By region, North America held the largest share of the global companion diagnostics market in 2024, benefiting from its advanced healthcare infrastructure, high healthcare spending, and a supportive regulatory environment that encourages the rapid adoption of new diagnostic technologies.

The companion diagnostics development market includes active players such as F. Hoffmann-La Roche Ltd.; QIAGEN N.V.; Agilent Technologies, Inc.; Abbott Laboratories; Illumina, Inc.; Myriad Genetics, Inc.; Sysmex Corporation; BioMerieux SA; Thermo Fisher Scientific Inc.; Labcorp; Quest Diagnostics; and Guardant Health, Inc.

Polaris Market Research has segmented the CDx development market report on the basis of type of service, analytical technique, target therapeutic area, end user, and region:

By Type of Service Outlook (Revenue - USD Million, 2020-2034)

Feasibility Studies

Assay Development

Analytical Validation

Clinical Validation

Manufacturing

By Analytical Technique Outlook (Revenue - USD Million, 2020-2034)

NGS

PCR

IHC

Flow Cytometry

Others

By Target Therapeutic Area Outlook (Revenue - USD Million, 2020-2034)

Oncological Disorders

Non-oncological Disorders

By End User Outlook (Revenue - USD Million, 2020-2034)

Industry Players

Non-Industry Players

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Companion Diagnostics (Cdx) Development Market Insights

• 4.1. Companion Diagnostics (Cdx) Development Market - Market Snapshot
• 4.2. Companion Diagnostics (Cdx) Development Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Growing Adoption of Personalized Medicine
    • 4.2.1.2. Rising Incidence of Cancer
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Complex and lengthy co-development and approval processes
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Companion Diagnostics (Cdx) Development Market Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Companion Diagnostics (Cdx) Development Market, by Type of Service

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
• 5.3. Feasibility Studies
  • 5.3.1. Global Companion Diagnostics (Cdx) Development Market, by Feasibility Studies, by Region, 2020-2034 (USD Million)
• 5.4. Assay Development
  • 5.4.1. Global Companion Diagnostics (Cdx) Development Market, by Assay Development, by Region, 2020-2034 (USD Million)
• 5.5. Analytical Validation
  • 5.5.1. Global Companion Diagnostics (Cdx) Development Market, by Analytical Validation, by Region, 2020-2034 (USD Million)
• 5.6. Clinical Validation
  • 5.6.1. Global Companion Diagnostics (Cdx) Development Market, by Clinical Validation, by Region, 2020-2034 (USD Million)
• 5.7. Manufacturing
  • 5.7.1. Global Companion Diagnostics (Cdx) Development Market, by Manufacturing, by Region, 2020-2034 (USD Million)

6. Global Companion Diagnostics (Cdx) Development Market, by Analytical Technique

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
• 6.3. NGS
  • 6.3.1. Global Companion Diagnostics (Cdx) Development Market, by NGS, by Region, 2020-2034 (USD Million)
• 6.4. PCR
  • 6.4.1. Global Companion Diagnostics (Cdx) Development Market, by PCR, by Region, 2020-2034 (USD Million)
• 6.5. IHC
  • 6.5.1. Global Companion Diagnostics (Cdx) Development Market, by IHC, by Region, 2020-2034 (USD Million)
• 6.6. Flow Cytometry
  • 6.6.1. Global Companion Diagnostics (Cdx) Development Market, by Flow Cytometry, by Region, 2020-2034 (USD Million)
• 6.7. Others
  • 6.7.1. Global Companion Diagnostics (Cdx) Development Market, by Others, by Region, 2020-2034 (USD Million)

7. Global Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
• 7.3. Oncological Disorders
  • 7.3.1. Global Companion Diagnostics (Cdx) Development Market, by Oncological Disorders, by Region, 2020-2034 (USD Million)
• 7.4. Non-oncological Disorders
  • 7.4.1. Global Companion Diagnostics (Cdx) Development Market, by Non-oncological Disorders, by Region, 2020-2034 (USD Million)

8. Global Companion Diagnostics (Cdx) Development Market, by End User

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• 8.3. Industry Players
  • 8.3.1. Global Companion Diagnostics (Cdx) Development Market, by Industry Players, by Region, 2020-2034 (USD Million)
• 8.4. Non-Industry Players
  • 8.4.1. Global Companion Diagnostics (Cdx) Development Market, by Non-Industry Players, by Region, 2020-2034 (USD Million)

9. Global Companion Diagnostics (Cdx) Development Market, by Geography

• 9.1. Key Findings
• 9.2. Introduction
  • 9.2.1. Companion Diagnostics (Cdx) Development Market Assessment, By Geography, 2020-2034 (USD Million)
• 9.3. Companion Diagnostics (Cdx) Development Market - North America
  • 9.3.1. North America: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
  • 9.3.2. North America: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
  • 9.3.3. North America: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
  • 9.3.4. North America: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.3.5. Companion Diagnostics (Cdx) Development Market - US
    • 9.3.5.1. US: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.3.5.2. US: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.3.5.3. US: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.3.5.4. US: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.3.6. Companion Diagnostics (Cdx) Development Market - Canada
    • 9.3.6.1. Canada: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.3.6.2. Canada: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.3.6.3. Canada: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.3.6.4. Canada: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• 9.4. Companion Diagnostics (Cdx) Development Market - Europe
  • 9.4.1. Europe: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
  • 9.4.2. Europe: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
  • 9.4.3. Europe: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
  • 9.4.4. Europe: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.4.5. Companion Diagnostics (Cdx) Development Market - UK
    • 9.4.5.1. UK: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.4.5.2. UK: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.4.5.3. UK: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.4.5.4. UK: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.4.6. Companion Diagnostics (Cdx) Development Market - France
    • 9.4.6.1. France: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.4.6.2. France: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.4.6.3. France: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.4.6.4. France: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.4.7. Companion Diagnostics (Cdx) Development Market - Germany
    • 9.4.7.1. Germany: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.4.7.2. Germany: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.4.7.3. Germany: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.4.7.4. Germany: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.4.8. Companion Diagnostics (Cdx) Development Market - Italy
    • 9.4.8.1. Italy: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.4.8.2. Italy: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.4.8.3. Italy: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.4.8.4. Italy: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.4.9. Companion Diagnostics (Cdx) Development Market - Spain
    • 9.4.9.1. Spain: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.4.9.2. Spain: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.4.9.3. Spain: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.4.9.4. Spain: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.4.10. Companion Diagnostics (Cdx) Development Market - Netherlands
    • 9.4.10.1. Netherlands: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.4.10.2. Netherlands: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.4.10.3. Netherlands: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.4.10.4. Netherlands: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.4.11. Companion Diagnostics (Cdx) Development Market - Russia
    • 9.4.11.1. Russia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.4.11.2. Russia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.4.11.3. Russia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.4.11.4. Russia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.4.12. Companion Diagnostics (Cdx) Development Market - Rest of Europe
    • 9.4.12.1. Rest of Europe: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.4.12.2. Rest of Europe: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.4.12.3. Rest of Europe: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.4.12.4. Rest of Europe: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• 9.5. Companion Diagnostics (Cdx) Development Market - Asia Pacific
  • 9.5.1. Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
  • 9.5.2. Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
  • 9.5.3. Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
  • 9.5.4. Asia Pacific: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.5.5. Companion Diagnostics (Cdx) Development Market - China
    • 9.5.5.1. China: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.5.5.2. China: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.5.5.3. China: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.5.5.4. China: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.5.6. Companion Diagnostics (Cdx) Development Market - India
    • 9.5.6.1. India: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.5.6.2. India: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.5.6.3. India: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.5.6.4. India: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.5.7. Companion Diagnostics (Cdx) Development Market - Malaysia
    • 9.5.7.1. Malaysia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.5.7.2. Malaysia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.5.7.3. Malaysia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.5.7.4. Malaysia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.5.8. Companion Diagnostics (Cdx) Development Market - Japan
    • 9.5.8.1. Japan: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.5.8.2. Japan: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.5.8.3. Japan: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.5.8.4. Japan: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.5.9. Companion Diagnostics (Cdx) Development Market - Indonesia
    • 9.5.9.1. Indonesia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.5.9.2. Indonesia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.5.9.3. Indonesia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.5.9.4. Indonesia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.5.10. Companion Diagnostics (Cdx) Development Market - South Korea
    • 9.5.10.1. South Korea: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.5.10.2. South Korea: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.5.10.3. South Korea: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.5.10.4. South Korea: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.5.11. Companion Diagnostics (Cdx) Development Market - Australia
    • 9.5.11.1. Australia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.5.11.2. Australia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.5.11.3. Australia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.5.11.4. Australia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.5.12. Companion Diagnostics (Cdx) Development Market - Rest of Asia Pacific
    • 9.5.12.1. Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.5.12.2. Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.5.12.3. Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.5.12.4. Rest of Asia Pacific: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• 9.6. Companion Diagnostics (Cdx) Development Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
  • 9.6.2. Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
  • 9.6.3. Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
  • 9.6.4. Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.6.5. Companion Diagnostics (Cdx) Development Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.6.5.2. Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.6.5.3. Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.6.5.4. Saudi Arabia: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.6.6. Companion Diagnostics (Cdx) Development Market - UAE
    • 9.6.6.1. UAE: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.6.6.2. UAE: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.6.6.3. UAE: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.6.6.4. UAE: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.6.7. Companion Diagnostics (Cdx) Development Market - Israel
    • 9.6.7.1. Israel: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.6.7.2. Israel: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.6.7.3. Israel: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.6.7.4. Israel: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.6.8. Companion Diagnostics (Cdx) Development Market - South Africa
    • 9.6.8.1. South Africa: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.6.8.2. South Africa: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.6.8.3. South Africa: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.6.8.4. South Africa: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.6.9. Companion Diagnostics (Cdx) Development Market - Rest of Middle East & Africa
    • 9.6.9.1. Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.6.9.2. Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.6.9.3. Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.6.9.4. Rest of Middle East & Africa: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
• 9.7. Companion Diagnostics (Cdx) Development Market - Latin America
  • 9.7.1. Latin America: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
  • 9.7.2. Latin America: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
  • 9.7.3. Latin America: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
  • 9.7.4. Latin America: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.7.5. Companion Diagnostics (Cdx) Development Market - Mexico
    • 9.7.5.1. Mexico: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.7.5.2. Mexico: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.7.5.3. Mexico: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.7.5.4. Mexico: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.7.6. Companion Diagnostics (Cdx) Development Market - Brazil
    • 9.7.6.1. Brazil: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.7.6.2. Brazil: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.7.6.3. Brazil: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.7.6.4. Brazil: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.7.7. Companion Diagnostics (Cdx) Development Market - Argentina
    • 9.7.7.1. Argentina: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.7.7.2. Argentina: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.7.7.3. Argentina: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.7.7.4. Argentina: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)
  • 9.7.8. Companion Diagnostics (Cdx) Development Market - Rest of Latin America
    • 9.7.8.1. Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by Type of Service, 2020-2034 (USD Million)
    • 9.7.8.2. Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by Analytical Technique, 2020-2034 (USD Million)
    • 9.7.8.3. Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by Target Therapeutic Area, 2020-2034 (USD Million)
    • 9.7.8.4. Rest of Latin America: Companion Diagnostics (Cdx) Development Market, by End User, 2020-2034 (USD Million)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. Abbott Laboratories
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. Agilent Technologies, Inc.
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. BioMerieux SA
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. F. Hoffmann-La Roche Ltd.
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Guardant Health, Inc.
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. Illumina, Inc.
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. Labcorp
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Myriad Genetics, Inc.
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. QIAGEN N.V.
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. Quest Diagnostics
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. Sysmex Corporation
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development
• 11.12. Thermo Fisher Scientific Inc.
  • 11.12.1. Company Overview
  • 11.12.2. Financial Performance
  • 11.12.3. Product Benchmarking
  • 11.12.4. Recent Development